Arrhythmia

Presented at AHA 2023, the topline analysis of the phase 2 AZALEA-TIMI 71 trial showed abelacimab significantly reduced bleeding in people with Afib at risk of stroke, compared with rivaroxaban.

In the phase 2 ReVeRA trial, etripamil nasal spray provided a marked reduction in ventricular rates among patients with atrial fibrillation and rapid ventricular rates.

Announced by Milestone Pharmaceuticals on October 24, 2023, the New Drug Application includes positive results on etripamil from the pivotal phase 3 RAPID trial.

The first-of-its-kind Aurora EV-ICD system offers a single-device, single procedure with a lead placed outside of the heart and veins.

Long-term data from NODE-302 suggests self-administered etripamil nasal spray for rapid heartbeat during PSVT well-tolerated and effective.

Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.

The CASTLE-HTx trial provides insight into the effects of catheter ablation in patients with AFib and end-stage heart failure, with potentially practice-changing implications.

Results of the FRAIL-AF trial at ESC Congress 2023 provide clinicians with further clarity into the effects of switching from vitamin K antagonists to NOACs in older patients with frailty and atrial fibrillation.

A study of more than 15,000 individuals suggests regular physical activity may help prevent the development of atrial fibrillation, as well as the incidence of stroke and MACE.

A new analysis suggests Black patients with NICM and an ICD had a high risk and burden of arrhythmia, with a lower survival rate, compared with White patients.

This cardiology case report from Brady Pregerson, MD, features man in his late-60s presenting to urgent care with 3 days of upper respiratory infection symptoms and one episode of near syncope. Check out the ECG and see if you can determine the correct diagnosis!

Clinical trial data suggest overweight and obese patients with atrial fibrillation who lose weight prior to a catheter ablation procedure experience better clinical outcomes.

An analysis of the UK Biobank found menstrual cycles less than 21 days or longer than 35 days were associated with a 19% higher risk of CVD compared with a regular menstrual cycle length.

An analysis of data from the NODE-303 trial provides insight into the effects of etripamil nasal spray in people with atrial fibrillation with rapid ventricular rates.

Presented at the European Stroke Conference, results of the ELAN trial offer evidence in support of early initiation, as opposed to later initiation, strategies for anticoagulation following acute ischemic stroke in patients with atrial fibrillation.

An analysis of more than 1 million AFib hospitalizations suggests those with large vessel vasculitis had a nearly 2-fold increase in risk of acute myocardial infarction and a more than 9-fold increase in risk of acute kidney injury.

An analysis of data from 3 European countries provides insight into the apparent increase in risk of atrial fibrillation associated with preterm births as well as LGA or SGA births.

Kim Zuber, PA-C, and Jane Davis, DNP, offer insight into the use of DOACs in people with atrial fibrillation and chronic kidney disease.

Patients who had severe COVID-19 infection requiring mechanical ventilation had a 16-fold risk of ventricular tachycardia within 6 months, according to new findings presented at EHRA 2023.

More than 50,000 patients with atrial fibrillation experienced reduced risks of stroke if they started statins within a year of diagnosis, compared with those who did not.

Results from the TEMPO-HCM study suggest that 30-day ECG monitoring in patients with HCM detects more arrhythmias than the standard 24-48 hours.

Using data from more than 800 older patients, new research is shining a light on the potential reduction in cognitive decline seen with the use of catheter ablation among patients with atrial fibrillation relative to medical management.

A retrospective analysis of more than 60 patients 21 years or younger who received a transcatheter leadless pacemaker provides an overview of the safety of such an approach in younger patient populations.

The expert consensus statement provides updated recommendations on evidence-based best practices for transcatheter LAAC, with a focus on endovascular devices.

A cost-effectiveness analysis of the EAST – AFNET 4 trial indicated the health benefits of early rhythm control come at reasonable additional costs compared to usual care.